View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
  3. Deal News
March 2, 2018updated 12 Aug 2019 10:39am

M&As this Week: Capio, BioStem Technologies, Virtus Health

Capio AB (publ) has entered an agreement to acquire 100% interest in healthcare and dental care services provider Novakliniken. 

Capio AB (publ) has entered an agreement to acquire 100% interest in healthcare and dental care services provider Novakliniken.

The healthcare services company will have 28 primary care centres and 220,000 listed patients in Skane region, upon completion of the acquisition in April 2018.

Both companies involved in the acquisition are based in Sweden.

BioStem Technologies Inc has agreed to purchase Grupo Impulso De Incentivacion Para Nuevas Tecnologias (GIINT).

GIINT will become a wholly owned subsidiary of BioStem upon completion of the acquisition.

Based in Mexico, the acquiring company is a life sciences company involved in the development of pharmaceutical and regenerative medicine products.

“GIINT will become a wholly owned subsidiary of BioStem upon completion of the acquisition.”

GIINT is based in Mexico and is a biotechnology company involved in stem cell research and development.

The acquisition will strengthen BioStem’s stem cell business.

Virtus Health Limited has signed an agreement to purchase 90% of Complete Fertility Limited (CFL) for £5m ($6.95m).

The business and assets related to fertility services provided by the University Hospital Southampton NHS Foundation Trust (UHS) are also part of the acquisition.

Virtus Health is an Australian healthcare services provider, while CFL is a fertility care provider based in the UK.

The transaction is expected to be closed by the end of this month.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena